Heroic theory of invention and scientific development

Lobe Sciences Provides Corporate Update to Investors and Stakeholders

Retrieved on: 
Monday, September 13, 2021

Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:
    Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts,
    We are pleased to say that 2021 has been a busy and transformative year for the Company.
  • During 2021, we have made significant progress on several fronts, and completed our transition to an integrated pharmaceutical development company.
  • We believe that psychedelic based therapeutics will bring a new era of treatment for many illnesses where current therapies are insufficient or unavailable.
  • Lobe Sciences is a life sciences company focused on psychedelic medicines.